Showing posts with label life expectancy. Show all posts
Showing posts with label life expectancy. Show all posts

Sunday, May 5, 2013

THE CURE! IS IT ALMOST HERE?

By Jake Wallis Simons (6:30PM BST 27 Apr 2013)

Source: http://www.telegraph.co.uk/health/healthnews/10022664/Scientists-hope-for-HIV-cure.html

Researchers are working on "novel strategies" to find a cure for HIV, with the first results expected “within months”.

Danish scientists are hoping for results that will show that “finding a mass-distributable and affordable cure to HIV is possible”.

They are conducting a clinical trial to test a “novel strategy” in which the HIV virus is "reactivated" from its hiding place within human DNA and potentially destroyed permanently by the immune system.

The move would represent a step forward in the attempt to find a cure for the virus, which causes Aids.

The scientists are currently conducting human trials on their treatment, in the hope of proving that it is effective. It has already been found to work in laboratory tests.

The technique involves unmasking the “reservoirs” formed by the HIV virus inside resting immune cells, bringing it to the surface of the cells. Once it comes to the surface, the body’s natural immune system may be able to kill the virus.

In vitro studies — those that use human cells in a laboratory — of the new technique proved so successful that in January, the Danish Research Council awarded the team 12 million Danish kroner (£1.5 million) to pursue their findings in clinical trials with human subjects.

These are now under way, and according to Dr Ole Søgaard, a senior researcher at the Aarhus University Hospital in Denmark and part of the research team, the early signs are “promising”.

“I am almost certain that we will be successful in activating HIV from the reservoirs," he said.

“The challenge will be getting the patients’ immune system to recognise the virus and destroy it. This depends on the strength and sensitivity of individual immune systems, as well as how large a proportion of the hidden HIV is unmasked.”

Fifteen patients are currently taking part in the trials, and ithe first results from the trial are expected to presented in the second half of 2013.

Dr Søgaard stressed that a cure is not the same as a preventative vaccine, and that raising awareness of unsafe behaviour, including unprotected sex and sharing needles, remains of paramount importance in combating HIV.

With modern HIV treatment, a patient can live an almost normal life, even into old age, with limited side effects.

However, if medication is stopped, HIV reservoirs become active and start to produce more of the virus, meaning that symptoms can reappear within two weeks.

Finding a cure would free a patient from the need to take continuous HIV medication, and save health services billions of pounds.

The technique is being researched in Britain, but studies have not yet moved on to the clinical trial stage. Five universities — Oxford, Cambridge, Imperial College, London, University College, London and King’s College, London — have jointly formed the Collaborative HIV Eradication of Reservoirs UK Biomedical Research Centre group (CHERUB), which is dedicated to finding an HIV cure.

They have applied to the Medical Research Council for funding to conduct clinical trials, which will seek to combine techniques to release the reservoirs of HIV with "immunotherapy", which gives patients a better chance of destroying the virus.

In addition, they are focusing on patients that have only recently been infected, as they believe this will improve chances of a cure. The group hopes to receive a funding decision in May.

“When the first patient is cured in this way it will be a spectacular moment,” says Dr John Frater, a clinical research fellow at the Nuffield School of Medicine, Oxford University, and a member of the CHERUB group.

“It will prove that we are heading in the right direction and demonstrate that a cure is possible. But I think it will be five years before we see a cure that can be offered on a large scale.”

The Danish team’s research is among the most advanced and fast moving in the world, as that they have streamlined the process of putting the latest basic science discoveries into clinical testing.

This means that researchers can progress more quickly to clinical trials, accelerating the process and reaching reliable results sooner than many others.

The technique uses drugs called HDAC Inhibitors, which are more commonly used in treating cancer, to drive out the HIV from a patient’s DNA and onto the surface of infected cells. The Danish researchers are using a particularly powerful type of HDAC inhibitor.

Five years ago, the general consensus was that HIV could not be cured. But then Timothy Ray Brown, an HIV sufferer — who has become known in the field as the Berlin Patient — developed leukaemia.

He had a bone marrow transplant from a donor with a rare genetic mutation that made his cells resistant to HIV. As a result, in 2007 Mr Brown became the first man to ever be fully cured of the disease.

Replicating this procedure on a mass scale is impossible. Nevertheless, the Brown case caused a sea change in research, with scientists focusing on finding a cure as well as suppressing the symptoms.

Two principal approaches are currently being pursued. The first, gene therapy, aims to make a patient’s immune system resistant to HIV. This is complex and expensive, and not easily transferrable to diverse gene pools around the world.

The second approach is the one being pursued by Dr Søgaard and his colleagues in Denmark, the CHERUB group in Britain, and by other laboratories in the United States and Europe.

 

Thursday, April 11, 2013

Life Expectancy for PLHIV

Many patients taking HIV drugs can now expect to live into their 70s

Michael Carter

Published: 25 July 2008

A large international study has provided evidence that people taking HIV treatment can now expect to live into their 60s and beyond. The study is published in the July 26th edition of The Lancet, and showed that an individual starting successful HIV treatment aged 20 would be expected to live to be 63, and that a patient initiating an anti-HIV drugs regimen aged 35 could live to the age of 67. It also provided evidence of the dramatic and continued decline in the risk of death amongst people with HIV since effective HIV treatment became available.

What is more, the researchers found that starting treatment with a CD4 cell count above 200 cells/mm3 would mean that a person aged 20 could expect to live to be 70, and that a 35 year-old could survive into their 72nd year.

Nevertheless, they still found that even in their most optimistic estimates, the life-expectancy of HIV-positive individuals was approximately ten years shorter than that of an HIV-negative individual. Furthermore injecting drug users and patients who started HIV treatment with lower CD4 cell counts had lower life-expectancies.

The author of an accompanying editorial calls these findings “exciting” and believes that they underline the importance of prompt diagnosis and treatment of HIV. He also suggests that the risk of death would be diminished and overall prognosis further improved by starting anti-HIV drugs with a CD4 cell count of 500 cells/mm3.

Almost immediately after multi-drug antiretroviral therapy became available in 1996, doctors observed dramatic reductions in rates of illness and death in HIV-positive patients treated with such drugs. A number of studies have shown that antiretroviral therapy has the potential to dramatically improve the prognosis of HIV-positive patients, but they have only considered patients in single cohorts or countries.

Therefore researchers from the Antiretroviral Cohort Collaboration which involves 14 large HIV cohort studies in Canada, Europe and the USA, looked at rates of mortality and the life-expectancy of over 43,000 patients who started HIV treatment for the first time between 1996 – 99, 2000 – 02 and 2002 – 05. They also looked at whether there were any patient characteristics which affected the risk of death or prognosis.

A total of 2056 (5%) patients died. The mortality rate fell from 16 deaths per 1000 person years between 1996- 99 to 10 per 1000 person years between 2002 – 05.

They also noted significant improvements in the prognosis for HIV-positive patients in the ten years of the study. Overall, a 20 year-old starting HIV treatment between 1996 and 2005 would be expected to live another 43 years. Between 1996 and 1999, they calculated that such a patient would live to be 56 years old, but in the period 2002 to 2005 this had improved to a little under 70 years.

There were also impressive improvements in the prognosis of 35 year-olds starting treatment, with an expectation of a further 32 years in life after HIV therapy was initiated. But, once more, prognosis improved over time from an expectation of a further 25 years of life in 1996 – 99, to 32 years by 2002- 05.

Patients who started HIV treatment with a low CD4 cell count (below 100 cells/mm3) had much higher mortality rates than patients initiating antiretroviral therapy with a CD4 cell count above 200 cells/mm3 (aged 20 – 44, 20 per 1000 person years vs. five per 1000 person years).

Furthermore a 20 year-old starting treatment with a CD4 cell count below 100 cells/mm3 would have a life-expectancy of 54 years compared to a life-expectancy of 70 years for a 20 year-old starting treatment with a CD4 cell count above 200 cells/mm3. The importance of CD4 cell count at the time of therapy initiation to prognosis was also seen in 35 year-olds, with patients with a CD4 cell count below 100 cells/mm3 expected to live until they were 62 compared to a prognosis of 72 years for patients with a CD4 cell count above 200 cells/mm3.

The investigators also found that women had a better prognosis than men, but that injecting drug users had a life-expectancy that was up to 20 years shorter than non-injecting drug users.

“There has been an improvement of outcomes with combination antiretroviral therapy between 1996 and 2005, characterised by a marked decrease in mortality rates” write the investigators. They attribute such reductions in mortality and improvements in life-expectancy to “improvements in therapy during the first decade of combination therapy.”

But they note that their study suggests that the prognosis of people taking antiretroviral therapy is still not normal. Picking up on this point, the author of the accompanying editorial highlights the findings of the SMART study which showed that patients with lower CD4 cell counts had a higher risk of serious non-HIV-related illnesses. The SMART study’s conclusions were one of the factors leading to HIV treatment guidelines recommending that antiretroviral therapy should be started at a CD4 cell count of 350 cells/mm3. The author notes the “clinical mischief of untreated HIV infection” and looks forward to the results of a clinical trial which could show if there is any benefit in starting HIV treatment at a CD4 cell count of 500 cells/mm3.

Reference

The Antiretroviral Cohort Collaboration. Life expectancy of individuals on combination therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet 372: 293 – 299, 2008.

Cooper DA. Life and death in the cART era. The Lancet 372: 266 – 267, 2008.